Stocktoria
Zivo Bioscience, Inc. ZIVO
Zivo Bioscience, Inc. (ZIVO) earns a Piotroski F-score of 4/9 (mixed financial health). It does not currently pay a dividend. FY2024 revenue was $157,220 at a -8513.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ZIVO | Zivo Bioscience, Inc. | 4/9 | — | — | — |
| VIVS | VivoSim Labs, INC. | 2/9 | — | — | — |
| ATYR | aTYR PHARMA INC | 1/9 | -19.49 | — | — |
| INMB | Inmune Bio, Inc. | 3/9 | — | — | — |
| ENTX | Entera Bio Ltd. | 2/9 | — | — | — |
| SNTI | Senti Biosciences Holdings, Inc. | 2/9 | — | — | — |
| CELZ | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. | 4/9 | -1.04 | — | — |
About Zivo Bioscience, Inc.
ZIVO Bioscience, Inc., together with its subsidiaries, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. It offers poultry gut health, avian influenza, bovine mastitis, canine joint health, human immune modification, human functional food ingredients, algal biomass for human food, and biomass for supporting skin health and anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Troy, Michigan.
FAQ
Is ZIVO financially healthy?
Zivo Bioscience, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak).
Does ZIVO pay a dividend?
No, Zivo Bioscience, Inc. does not currently pay a dividend.
How profitable is ZIVO?
In FY2024, Zivo Bioscience, Inc. had a net margin of -8513.4%.
Is ZIVO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Zivo Bioscience, Inc.: a Piotroski F-score of 4/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2024-12-31. Facts plus Stocktoria's own computed scores — not investment advice.